BG Medicine Announces Preliminary Decision by CMS on Reconsideration of Reimbursement for BGM Galectin-3 Test

Published: Sep 30, 2013

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

WALTHAM, Mass., Sept. 30, 2013 (GLOBE NEWSWIRE) -- BG Medicine, Inc. (Nasdaq:BGMD) announced today that the Centers for Medicare and Medicaid Services (CMS) have made a preliminary decision to set the Medicare payment rate for the Company's BGM Galectin-3® test at the amount of a cross walked test whose 2013 national limitation amount is $30.24, subject to a final determination by CMS by year-end 2013. The new payment rate, if finalized, will replace the BGM Galectin-3® test's national limitation amount of $17.80 that was effective in 2013.

Help employers find you! Check out all the jobs and post your resume.

Back to news